-

07:21:51 AM

TNGX Stock News

TNGX - Tango Therapeutics Inc

03/27/23 7:00 AM

Nasdaq : TNGX

earnings

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company

RHEA-AI

positive

03/14/23 8:11 PM

Nasdaq : TNGX

clinical trial

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida. Abstract

RHEA-AI

neutral

03/10/23 10:15 PM

Nasdaq : TNGX

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that it is aware of the current situation affecting Silicon Valley Bank

RHEA-AI

neutral

03/06/23 7:00 AM

Nasdaq : TNGX

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective March 1, 2023, the Compensation Committee of Tango

RHEA-AI

very positive

03/01/23 7:00 AM

Nasdaq : TNGX

conferences

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of

RHEA-AI

neutral

02/28/23 7:00 AM

Nasdaq : TNGX

management

Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. as President of

RHEA-AI

very positive

02/02/23 7:00 AM

Nasdaq : TNGX

conferences

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of

RHEA-AI

neutral

01/25/23 7:00 AM

Nasdaq : TNGX

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

RHEA-AI

very positive

11/10/22 7:00 AM

Nasdaq : TNGX

earnings

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers – – TNG348 declared as a USP1

RHEA-AI

neutral

11/07/22 7:00 AM

Nasdaq : TNGX

conferences

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of

RHEA-AI

neutral